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Received March 9, 2014; accepted June 16, 2015AbstractBackground: Gadoxetic acid is one of the hepatobiliary-specific agents and so can be used for contrast-enhanced magnetic resonance chol-
angiography (CE-MRC). The aim of our study was to compare the performance of CE-MRC with that of T2-weighted magnetic resonance
cholangiography (T2W-MRC), and also to ascertain the effectiveness of both modalities combined for visualizing anatomic structures of the
biliary tree in patients with liver cirrhosis.
Methods: Fifty-six patients underwent CE-MRC and T2W-MRC imaging. In the CE-MRC studies, hepatobiliary phase images were acquired 20
minutes after contrast injection. Two radiologists first evaluated the T2W-MRC and CE-MRC images separately in random order, and then they
reviewed both images together 8 weeks later. The readers graded the quality of visualization of each biliary duct and the entire biliary tree
(overall rating) using a five-point scale. Images with a grade of 3 or 4 were considered to provide sufficient visualization for clinical application,
and those with a grade of 2 or less were considered to provide insufficient visualization. Laboratory data, ChildePugh classification, and model
for end-stage liver disease score were also recorded.
Results: The overall rating of T2W-MRC was significantly higher than that of CE-MRC ( p < 0.001), although combined T2W/CE-MRC
provided better visualization of biliary segments than T2W-MRC alone ( p ¼ 0.025). There were no significant differences between liver
function and the overall rating of CE-MRC.
Conclusion: CE-MRC is not superior to conventional T2W-MRC with respect to biliary visualization in patients with liver cirrhosis. However, a
combination of T2W-MRC and CE-MRC provides significantly better visualization of biliary structures than T2W-MRC alone.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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T2-weighted magnetic resonance cholangiography (T2W-
MRC) is a widely accepted noninvasive method for imaging
choledocholithiasis, biliary tract obstruction and dilatation,
and biliary anatomy.1e5 However, the technique is associated
with several interpretive pitfalls, which may result inociation. All rights reserved.
727W.-P. Wu et al. / Journal of the Chinese Medical Association 78 (2015) 726e731diagnostic errors.6e8 In addition, T2W-MRC yields static
images in contrast to real-time images obtained using endo-
scopic retrograde cholangiopancreatography or percutaneous
transhepatic cholangiography. Moreover, T2W-MRC cannot
discriminate between different kinds of fluids (for example,
bile leakage from small ascites), and soft tissue contrast can be
lost with a very long echo time.
Several studies have shown that contrast-enhanced mag-
netic resonance cholangiography (CE-MRC) has the potential
to provide a “one stop shop” for diagnosing anatomic and
functional abnormalities of the biliary tree.9e13 Gadolinium-
ethoxybenzyl-diethylenetriaminepentaacetic acid (gadoxetic
acid) and gadobenate dimeglumine can be used as intra-
vasculareinterstitial contrast agents for dynamic magnetic
resonance imaging (MRI) and as hepatocyte-specific contrast
agents for MRC. However, because of earlier onset and longer
duration, gadoxetic acid may provide better visualization of
biliary structures within a shorter period of time than
gadobenate dimeglumine.14
Recent studies have shown that CE-MRC with gadoxetic
acid is an effective technique for evaluating biliary tract
anatomy, obstruction, and active bile leakage in patients with
normal liver function.15e18 Few studies, however, have
investigated the quality of bile duct visualization using CE-
MRC in patients with liver cirrhosis,19 and to the best of our
knowledge, no studies have compared the quality of visuali-
zation obtained by CE-MRC with that obtained by T2W-MRC
in patients with cirrhosis. The purpose of our study was to
compare the performance of CE-MRC with that of T2W-
MRC, and assess the effectiveness of both modalities com-
bined for visualizing anatomic structures of the biliary tree in
patients with liver cirrhosis.
2. Methods2.1. PatientsThis retrospective study was approved by the Institutional
Review Board of our hospital. A total of 60 consecutive pa-
tients underwent gadoxetic acid-enhanced MRI of liver for
suspected focal liver lesions during a 16-month period (from
October 2008 to January 2011). The focal lesions were diag-
nosed either histologically or radiologically, and comprised
hepatocellular carcinoma in 51 patients, hep-
atocholangiocarcinoma in two patients, dysplastic nodules in
two patients, hemangioma in one patient, and focal nodular
hyperplasia in one patient. No abnormal pathology was
detected in three patients. The inclusion criteria for our study
were as follows: (1) patients must have liver cirrhosis; (2)
laboratory and MRI studies should have been conducted
within a 2-week period; and (3) both gadoxetic acid-enhanced
MRC and T2W-MRC images should be available for review. A
total of 56 patients fulfilled the criteria and were enrolled into
the study. The cohort comprised 43 men and 13 women in the
age range of 30e82 years (mean age, 59.9 years). The diag-
nosis of cirrhosis was established histologically in 43 patients
(biopsy, n ¼ 14; surgical resection, n ¼ 21; livertransplantation, n ¼ 8) and was based on the combination of
clinical, laboratory, endoscopic, and ultrasound findings in 13
patients. The clinical diagnosis of liver cirrhosis was made in
patients with chronic liver disease who had one or more of the
following clinical findings: firm liver and ascites, signs of
collateral circulation, prothrombin index <85%, ultrasono-
graphic evidence of irregular liver surface and heterogeneity,
and endoscopic evidence of esophageal varices.20 No biliary
duct dilatations were observed in any of the 56 patients.
The underlying causes of liver cirrhosis were hepatitis B
(n ¼ 28), hepatitis C (n ¼ 16), hepatitis B and hepatitis C
combined (n ¼ 4), alcoholic chronic hepatitis (n ¼ 4), and
cryptogenic cirrhosis (n ¼ 4). Hepatic function was classified
as ChildePugh Class A in 31 patients, ChildePugh Class B in
13 patients, and ChildePugh Class C in 12 patients.2.2. MRI techniqueAll MR studies were performed with a 1.5-T MR scanner
(Gyroscan ACS-NT Intera; Philips, Best, The Netherlands)
and a phased-array body coil. Navigator-triggered three-
dimensional (3D) T2W-MRC images were obtained during
free breathing (1800/650; refocusing flip angle, 90; field of
view (FOV), 300 mm; matrix, 512  512; echo train length,
115; slab thickness, 80 mm; section thickness, 1 mm; inter-
polation to 80 sections of 1-mm intervals; parallel acquisition
technique factor, 2; no phase wrap option; acquisition time,
260e300 seconds). A whole-volume maximum-intensity pro-
jection reformation was applied in the coronal plain.
For contrast-enhanced MRI with gadoxetic acid, all patients
received a 0.025 mmol/kg (0.1 mL/kg) dose of gadoxetic acid
(Primovist; Bayer Schering Pharma, Berlin, Germany). The
contrast agent was administered as a manual bolus injection at a
speed of approximately 2 mL/second through peripheral veins.
The line was flushed with 20 mL of 0.9% saline. Dynamic 3D
T1W fast-field echo imaging (repetition time (TR)/echo time
(TE), 10.2e10.7 milliseconds/5 milliseconds; slice thickness,
3 mm; matrix, 192  256; number of excitations (NEX), 1; flip
angle, 15; FOV, 38e40 cm) was carried out before and 25e30
seconds (arterial phase), 55e60 seconds (portal phase), and
85e90 seconds (venous phase) after the injection of the contrast
agent. Delayed MRI at 20 minutes after the application of
gadoxetic acid was performed with the same parameters as used
for the dynamic study. CE-MRC images were reconstructed
using a coronal oblique multiplanar reformatted image gener-
ated from the 20-minute delayed 3D T1W images.2.3. Imaging evaluationImaging analysis was performed on a dual-screen diag-
nostic workstation (GE Healthcare, Milwaukee, WI, USA).
Images were evaluated by two experienced radiologists (with
15 and 7 years of clinical experience in abdominal MR) who
were not aware of the patients' clinical characteristics or lab-
oratory results. Readers categorized the MRC images into
three groups: T2W-MRC, CE-MRC, and a combined group
(T2W-MRC plus CE-MRC). Image review was based on
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projections. To reduce reviewer bias, T2W-MRC and CE-
MRC images were arranged in random order and evaluated
separately. Approximately 8 weeks later, the radiologists
reviewed the combined T2W-MRC and CE-MRC images.
The two readers were asked to evaluate all MR image sets
and record the bile duct visualization grading scores. The
following structures were evaluated: the common bile duct
(CBD), the common hepatic duct (CHD), and the right and left
hepatic ducts and their secondary branches. The quality of
visualization of the bile ducts was assessed using a five-point
Likert-type scale as follows: Grade 0, nonvisualization of the
ducts; Grade 1, partial visualization of less than half of the
duct, high to moderate artifacts, or extensive superimposition
of other anatomic structures; Grade 2, visualization of more
than half of the duct, few to moderate artifacts, or moderate
superimposition of other anatomic structures; Grade 3, total
visualization of its entire length with ambiguous margins, few
artifacts, or minimal superimposition of other anatomic
structures; and Grade 4, excellent visualization with clear
margins.9 Disagreements in imaging evaluation between the
two radiologists were resolved by consensus with a third
radiologist. The images of the bile ducts ranked as 3 or 4 were
grouped as “sufficient visualization” for clinical application,
and those ranked as 2 or less were grouped as “insufficient
visualization” (Fig. 1).
In addition to grading the quality of visualization of each
biliary duct, the readers also graded the visualization of the
entire biliary tree (overall rating). When all the segments,
including CBD, CHD, and right and left hepatic ducts, could
be visualized, the overall rating was deemed to be “sufficient.”
If any one of the segments could not be visualized, the overall
rating was deemed insufficient.19
Patients' charts were reviewed and the following serum
parameters were recorded: serum total bilirubin, platelet
count, creatinine, prothrombin time, glutamic oxaloacetic
transaminase, glutamic pyruvic transaminase, and albumin.
ChildePugh classification, ChildePugh score, and model for
end-stage liver disease (MELD) score were also determined
for each patient. A patient's MELD score is calculated usingFig. 1. A 52-year-old man with histologically proven liver cirrhosis (ChildePugh C
MRC clearly depicts the common bile duct, common hepatic duct, and bilateral hep
biliary excretion after application of gadoxetic acid in the hepatobiliary phase. Th
bilateral hepatic ducts by CE-MRC was rated to be as good as the quality of visua
enhanced magnetic resonance cholangiography; MELD ¼ model for end-stage livvalues for serum creatinine, total bilirubin, and the interna-
tional normalized ratio as follows: MELD ¼ 9.57 
Loge(creatinine) þ 3.78  Loge(total bilirubin) þ 11.2 
Loge(international normalized ratio) þ 6.43.212.4. Statistical analysisWe used a weighted kappa statistic to measure interviewer
agreement according to each biliary segment. Serial weighted
pairwise comparisons across two reviewers were performed,
and an average kappa value was calculated. A kappa value of
0.00 indicated no agreement; 0.01e0.20, slight agreement;
0.21e0.40, fair agreement; 0.41e0.60, moderate agreement;
0.61e0.80, good agreement; and 0.81e1.00, excellent agree-
ment. Using T2W-MRC as a standard reference, the overall
ratings and ratings for visualization of biliary segments were
compared between CE-MRC and T2W-MRC and between the
combined group and T2W-MRC using the Wilcoxon signed-
rank test. Analysis of the relationships between the overall
rating of CE-MRC and various liver function parameters was
also performed using the Wilcoxon signed-rank test. A p value
of <0.05 was considered to indicate statistical significance. All
statistical analyses were performed using the statistical pack-
age SPSS for Windows (version 20.0.0; SPSS, Chicago, IL,
USA).
3. Results
A total of 328 biliary segments in 56 patients were evalu-
ated. Eight segments were missing in four patients because
they had undergone right (n ¼ 3) or left (n ¼ 1) hemi-
hepatectomy. The bile ducts were not visible on T2W-MRC
images in three patients (5.4%) or on CE-MRC images in
two patients (3.6%). The inter-reviewer agreement for the
degree of segmental visualization reached good to excellent
levels (k ¼ 0.76e0.94) (Table 1). In two of the three patients
for whom the bile ducts were not visible on T2W-MRC im-
ages, there was sufficient visualization for anatomical diag-
nosis on CE-MRC images (Fig. 2).lassification A, MELD score 7, total bilirubin, 1.17 mg/dL). (A) T2-weighted
atic ducts (all ranked Grade 4). (B) CE-MRC in the coronal plane demonstrates
e quality of visualization of the common bile duct, common hepatic duct, and
lization of those structures by T2-weighted MRC. CE-MRC ¼ gadoxetic acid-
er disease; MRC ¼ magnetic resonance cholangiography.
Table 1
Interobserver agreement by kappa analysis.
Segment k value
T2W-MRC CE-MRC Combined T2W-MRC
and CE-MRC
CBD 0.94 1.00 0.93
CHD 0.90 0.76 0.78
RHD 0.87 0.85 0.82
LHD 0.92 0.74 0.76
Second branch of RHD 0.88 0.84 0.82
Second branch of LHD 0.84 0.89 0.84
CBD ¼ common bile duct; CE-MRC ¼ contrast-enhanced magnetic resonance
cholangiography; CHD ¼ common hepatic duct; LHD ¼ left hepatic duct;
RHD ¼ right hepatic duct; T2W-MRC ¼ T2-weighted magnetic resonance
cholangiography.
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the overall ratings in the T2W-MRC group, CE-MRC group,
and combined group are shown in Table 2. For segment-based
visualization of each bile duct, the combined group showed
significantly better visualization of the CBD, CHD, and
bilateral hepatic ducts than T2W-MRC alone. However, noFig. 2. An 81-year-old man with liver cirrhosis underwent right hepatic lobectomy
total bilirubin, 0.75 mg/dL). (A) T2W-MRC shows no visualization of any bile ducts
thick bile in the biliary tree. (B) Gadoxetic acid-enhanced MRC in the coronal plan
duct, and left hepatic duct (all ranked Grade 3). Both CE-MRC alone and combined
enhanced magnetic resonance cholangiography; MELD ¼ model for end-stage liv
weighted magnetic resonance cholangiography.
Table 2
Diagnostic performance of the overall rating and each segment for T2W-MRC, C
Segments n Sufficient visualization
T2W-MRC CE-MRC Combined CE/T2
CBD 56 50 (89.3%) 43 (76.8%) 55 (98.2%)
CHD 56 45 (80.4%) 46 (82.1%) 52 (92.9%)
RHD 53 35 (66.0%) 27 (50.9%) 44 (78.6%)
LHD 55 39 (70.9%) 25 (45.5%) 44 (78.6%)
Second branch of RHD 53 12 (22.6%) 7 (13.2%) 14 (25%)
Second branch of LHD 55 13 (23.6%) 7 (12.7%) 15 (26.8%)
Overall rating 56 37 (66.1%) 20 (35.7%) 40 (71.4%)
Overall rating taking into account the total performance of CBD, CHD, RHD, and
CBD ¼ common bile duct; CE-MRC ¼ gadoxetic acid-enhanced magnetic resonan
RHD ¼ right hepatic duct; T2W-MRC ¼ T2-weighted magnetic resonance cholansignificant differences in visualization of the secondary
branches were found. In addition, there were no significant
differences between CE-MRC and T2W-MRC in visualization
of any of the biliary segments, with the exception of the left
hepatic duct ( p ¼ 0.004).
Based on the overall rating, CE-MRC alone provided suf-
ficient visualization of the biliary tree in only 35.7% (20/56) of
patients, whereas T2W-MRC alone provided sufficient visu-
alization in 66.1% (37/56) of patients. However, T2W-MRC/
CE-MRC allowed for sufficient visualization in 71.4% (40/
56) of patients. The overall rating of combined imaging was
significantly better than that of T2W-MRC imaging alone
( p ¼ 0.025), and the overall rating of T2W-MRC alone was
significantly better than that of CE-MRC alone ( p < 0.001).
We then analyzed whether liver function affected the
quality of visualization of the biliary tract on CE-MRC im-
ages. We found that although the number of images with
insufficient visualization tended to be higher in patients with
ChildePugh classification C, higher ChildePugh scores,
higher MELD scores, and higher total bilirubin levels, there
were no significant differences between liver function pa-
rameters and visualization quality (Table 3).for hepatocellular carcinoma (ChildePugh Classification A, MELD score 12,
but clearly depicts the pancreatic duct. Lack of visualization is probably due to
e demonstrates biliary enhancement of the common bile duct, common hepatic
CE/T2W-MRC provided sufficient visualization. CE-MRC ¼ gadoxetic acid-
er disease; MRC ¼ magnetic resonance cholangiography; T2W-MRC ¼ T2-
E-MRC, and combined CE/T2W-MRC.
p
W-MRC T2W-MRC vs. CE-MRC Combined CE/T2W vs. T2W-MRC
0.09 0.025
0.782 0.014
0.117 0.003
0.004 0.025
0.096 0.157
0.058 0.157
<0.001 0.025
LHD.
ce cholangiography; CHD ¼ common hepatic duct; LHD ¼ left hepatic duct;
giography.
Table 3
Comparison of various liver function parameters and the overall rating of
gadoxetic acid-enhanced MRC.
Contrast-enhanced MRC p
Insufficient
(N ¼ 36)
Sufficient
(N ¼ 20)
ChildePugh score 7.17 ± 2.48 6.60 ± 2.06 0.541
MELD score 10.72 ± 4.79 9.95 ± 3.49 0.816
Total bilirubin (mg/dL) 1.54 ± 2.01 1.44 ± 1.34 0.431
Albumin (g/dL) 3.63 ± 0.63 3.52 ± 0.75 0.521
ChildePugh Class A or B 28 (77.8%) 16 (80.0%) >0.99
C 8 (22.2%) 4 (20.0%)
Platelet count Low 20 (55.6%) 15 (75.0%) 0.150
Prothrombin time Prolonged 6 (16.7%) 4 (20.0%) 0.733
GOT Abnormal 17 (47.2%) 12 (60.0%) 0.412
GPT Abnormal 19 (52.8%) 11 (55.0%) 0.873
ChildePugh score, MELD score, total bilirubin, and albumin value were
expressed as mean ± standard deviation.
Low platelet count indicates a count of <150  103/mL; prolonged PT in-
dicates a PT value of >12 seconds; abnormal GOT or GPT indicates a level of
>40 U/L.
GOT ¼ glutamic oxaloacetic transaminase; GPT ¼ glutamic pyruvic trans-
aminase; MELD ¼ model for end-stage liver disease; MRC ¼ magnetic
resonance cholangiography; PT ¼ prothrombin time.
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The differences in the performance of T2W-MRC and CE-
MRC may be due to the different imaging techniques. T2W-
MRC benefits from a sufficiently long TE and displays only
the fluid in the bile ducts with high signal intensity. When
gadoxetic acid is used as a hepatobiliary contrast agent for
functional imaging, it enhanced the biliary lumen via excretion
into the bile ducts by a cellular process after its uptake by the
hepatocyte.
Our results showed that the combination of T2W-MRC and
CE-MRC provides better visualization of the biliary tree than
T2W-MRC alone, especially for visualizing the CBD, CHD, and
bilateral hepatic bile ducts. Gupta et al22 reported that a combi-
nation of T2W images and gadolinium-enhanced T1W images
during the hepatocyte phase is generally required for optimal
evaluation of the biliary system in patients with normal liver
function. CE-MRC can also increase the radiologist's confidence,
especially in the evaluation of choledocholithiasis or identifica-
tion of anatomic biliary ductal variants for living donors.13,16,17
We found that the combination of CE-MRC and T2W-MRC
did not significantly improve visualization of small intrahepatic
bile ducts of the bilateral second branches relative to T2W-
MRC alone ( p ¼ 0.157). In an attempt to improve visualiza-
tion of the small intrahepatic bile ducts, Mangold et al16 re-
ported that second-and third-order bile ducts are more accurate
in CE-MRC when delayed images are obtained 1.5 hours after
the application of gadoxetic acid. In our study, the delay was
only for 20 minutes, which might be the reason why the small
intrahepatic bile ducts were poorly depicted in our study.
The overall rating of T2W-MRC was higher than that of
CE-MRC alone in patients with liver cirrhosis for two reasons.
It is well understood that decreased and delayed liver paren-
chymal enhancement is related to liver dysfunction, leading todecreased excretion of gadoxetic acid into the biliary tract. In
our study, only 35.7% of patients with liver cirrhosis had CE-
MRC images with sufficient visualization of the biliary tree.
Tschirch et al19 also reported that in only about 40% of pa-
tients in the cirrhosis group the overall CE-MRC image quality
was rated as sufficient for anatomical diagnosis within 30
minutes of contrast application. The second reason why the
overall rating of CE-MRC was inferior to that of T2W-MRC is
that enhancement of liver parenchyma decreases the contrast-
noise ratio of the biliary tree. In an in vivo Phase I clinical
evaluation performed in healthy volunteers receiving different
doses of gadoxetic acid, Bollow et al23 reported that low doses
(10 mmol/kg) of gadoxetic acid were helpful for assessing the
intrahepatic bile ducts. Further clinical studies are needed to
determine whether low doses of gadoxetic acid improve the
quality of CE-MRC images in patients with liver cirrhosis.
In our study, T2W-MRC images did not show the biliary
tree in three patients. Studies have shown that signal loss in the
bile ducts could be due to air bubbles, hemorrhage, or
debris.24e26 The possibility of signal loss due to air bubbles or
hemorrhage in our study was excluded on abdominal ultra-
sound and conventional T1W, T2W, and dynamic MRI. Thick
bile inside the biliary tree is the most likely reason for lack of
visualization. Interestingly, there was sufficient visualization
on CE-MRC images in two of the three patients. We suggest
that the hepatobiliary phase of T1W MRI with gadoxetic acid
might be a complementary method in clinical practice, espe-
cially when T2W-MRC images are inconclusive.
In this study, we evaluated the relationship between various
laboratory data representing liver function and the overall
rating of CE-MRC. We found that although the number of
images with insufficient visualization tended to be higher in
patients with ChildePugh classification C, higher ChildePugh
scores, higher MELD scores, and higher total bilirubin levels,
there were no significant differences between liver function
parameters and visualization quality. One reason for this may
be that there were few patients with ChildePugh classification
C in our study. In addition, few studies have evaluated the
relation between various laboratory parameters of liver func-
tion and the uptake and excretion of gadoxetic acid in patients
with liver cirrhosis.19,27e29 Their results showed disagree-
ments about the relationships between laboratory parameters
and the uptake or excretion of gadoxetic acid. Even Motosugi
et al27 reported that no biological markers of liver function are
significantly correlated with liver enhancement.
We acknowledge that our study had the following limita-
tions. First, hepatocyte phase imaging was performed 20 mi-
nutes after the injection of contrast agent. A longer delay may
be needed for patients with liver cirrhosis. The optimal timing
for biliary imaging in patients with impaired liver function
should be studied in the future. Second, liver cirrhosis was not
histologically confirmed in all the patients.
In conclusion, CE-MRC is not superior to conventional
T2W-MRC in biliary visualization in patients with liver
cirrhosis. However, a combination of T2W-MRC and CE-
MRC provides significantly better visualization of biliary
structures than T2W-MRC alone. The hepatobiliary phase of
731W.-P. Wu et al. / Journal of the Chinese Medical Association 78 (2015) 726e731T1W MRI with gadoxetic acid might be a complementary
method in clinical practice, especially when T2W-MRC im-
ages are inconclusive.
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